Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.

Trial Profile

Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2012

At a glance

  • Drugs NN 7128 (Primary)
  • Indications Haemorrhage
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Sep 2012 Not official study title and study phase estimated
    • 04 Sep 2012 New trial record
    • 01 Aug 2012 Results published in Transfusion.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top